Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 23;12(11):3478.
doi: 10.3390/cancers12113478.

Total Pelvic Exenteration, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy for Rectal Cancer with Associate Peritoneal Metastases: Surgical Strategies to Optimize Safety

Jean-Jacques Tuech  1 , Jean Pinson  1 , François-Xavier Nouhaud  2 , Gregory Wood  3 , Thomas Clavier  3 , Jean-Christophe Sabourin  4 , Frederic Di Fiore  5 , Matthieu Monge  1 , Eloïse Papet  1 , Julien Coget  1
Affiliations

Total Pelvic Exenteration, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy for Rectal Cancer with Associate Peritoneal Metastases: Surgical Strategies to Optimize Safety

Jean-Jacques Tuech et al. Cancers (Basel). .

Abstract

Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a curative treatment option for patients with peritoneal carcinomatosis. Total pelvic exenteration (TPE) is an established treatment option for locally advanced pelvic malignancy. These two procedures have high mortality and morbidity, and therefore, their combination is not currently recommended. Herein, we reported our experience on TPE associated with CRS/HIPEC with a critical analysis for rectal cancer with associate peritoneal metastases.

Methods: From March 2006 to August 2020, 319 patients underwent a CRS/HIPEC in our hospital. Among them, 16 (12 men and four women) underwent an associated TPE. The primary endpoints were perioperative morbidity and mortality.

Results: There was locally recurrent rectal cancer in nine cases, six locally advanced primary rectal cancer, and a recurrent appendiceal adenocarcinoma. The median Peritoneal Cancer Index (PCI) was 8. (4-16). Mean duration of the surgical procedure was 596 min (420-840). Complete cytoreduction (CC0) was achieved in all patients, while clear resection (R0) margins on the resected pelvic organs were achieved in 81.2% of cases. The median hospital stay was 46 days (26-129), and nine patients (56.2%) experienced severe complications (grade III to V) that led to death in two cases (12.5%). The total reoperation rate for patients was 6/16 (37.5%) and 3/16 (18.75%) with percutaneous radiological-guided drainage.

Conclusions: In summary, TPE/extended TPE (ETPE) associated with CRS/HIPEC may be a reasonable procedure in selected patients at expert centers. Pelvic involvement should not be considered a definitive contraindication for CRS/HIPEC in patients with resectable peritoneal surface diseases if a R0 resection could be achieved on all sites. However, the morbidity and the mortality are high with this combination of treatment, and further research is needed to assess the oncologic benefit and quality of life before such a radical approach can be recommended.

Keywords: cytoreductive surgery; empty pelvis syndrome; hyperthermic intraperitoneal chemotherapy; ileal conduit; pelvic exenteration; peritoneal carcinomatosis; peritoneal metastases; urinary leakage.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Glehen O., Gilly F.N., Boutitie F., Bereder J.M., Quenet F., Sideris L., Mansvelt B., Lorimier G., Msika S., Elias D. French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients. Cancer. 2010;116:5608–5618. - PubMed
    1. Moran B., Cecil T., Chandrakumaran K., Arnold S., Mohamed F., Venkatasubramaniam A. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis. 2015;17:772–778. - PubMed
    1. Chua T.C., Saxena A., Schellekens J.F., Liauw W., Yan T.D., Fransi S., Zhao J., Morris D.L. Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: Towards a new perspective of this treatment. Ann. Surg. 2010;251:101–106. - PubMed
    1. Verwaal V.J., van Tinteren H., Ruth S.V., Zoetmulder F.A. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J. Surg. Oncol. 2004;85:61–67. - PubMed
    1. Sugarbaker P.H., Alderman R., Edwards G., Marquardt C.E., Gushchin V., Esquivel J., Chang D. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann. Surg. Oncol. 2006;13:635–644. - PubMed

LinkOut - more resources